Company description

BioMarin Pharmaceutical Inc. (BMRN) is a global biotechnology company that focuses on developing and commercializing innovative therapies for rare and ultra-rare genetic diseases. Founded in 1997, BioMarin has a strong track record of success in the rare disease space, with a portfolio of products that have transformed the lives of patients and their families. The company is dedicated to making a meaningful difference in the lives of patients and their families by using advanced science and technology to tackle some of the most challenging diseases. With a strong commitment to research and development, BioMarin has a robust pipeline of potential treatments for various rare diseases, including hemophilia, Batten disease, and phenylketonuria (PKU). The company's success is also driven by its global presence, with operations in North America, Europe, Asia-Pacific, and Latin America. BioMarin's unwavering commitment to improving the lives of rare disease patients, coupled with its strong financial performance, makes it a leader in the biotechnology industry. As the company continues to advance its pipeline and expand its global reach, BioMarin remains at the forefront of cutting-edge research and development in the rare disease space.